Cabiralizumab by Bristol-Myers Squibb for Melanoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Cabiralizumab overview

Cabiralizumab (CSF1R antibody) is under development for the treatment of pigmented villonodular synovitis, diffuse type tenosynovial giant cell tumor, biliary tract cancer, other inflammatory disorders, triple-negative breast cancer, relapsed or refractory multiple myeloma, solid tumors including non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, colorectal cancer, ovarian cancer, glioblastoma multiforme (GBM), peripheral T cell lymphoma (PTCL) and renal cell carcinoma. The drug candidate is administered as an IV infusion. The drug candidate is a humanized monoclonal antibody targeting colony stimulating factor 1 receptor (CSF1R). The drug candidate is based on receptor-ligand matching technology. The drug candidate was also under development for the treatment of rheumatoid arthritis and multiple sclerosis, metastatic adenocarcinoma of the pancreas, bile duct cancer (cholangiocarcinoma).

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

For a complete picture of Cabiralizumab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.